Modular Medical’s GLP-1 Pump Study: A Fresh Take on Diabetes & Obesity Management Innovation – ( $MODD $LLY $NVS )

Modular Medical, Inc. (NASDAQ: MODD) , a company with a knack for shaking up the insulin delivery market, is set to make a splash at the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The company unveiled findings from an exploratory study that could have meaningful implications for diabetes and obesity management, all with the flair of their user-friendly, FDA-cleared patch pump—designed not just for the tech-savvy, but for the “almost-pumpers” among us who crave simplicity and affordability. The ADA 85th Scientific Sessions is the world’s largest diabetes conference, bringing together over 11,000 physicians, scientists, and healthcare professionals to explore cutting-edge advancements in diabetes research, treatment, and care. Modular Medical’s participation underscores its commitment to driving innovation in diabetes therapies and improving patient outcomes.

A Mouse, a Pump, and a GLP-1 Agonist Walk Into a Lab…

At the heart of Modular Medical’s presentation is a poster titled “Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse.” Led by Dr. David Maggs, this study explores whether delivering a short-acting GLP-1 receptor agonist via pump can tip the scales—literally—in the battle against obesity and glucose intolerance. The research zeroes in on diet-induced obese mice, examining how this delivery method affects their weight, food intake, and glucose tolerance. While the mice may not have had much say in the matter, the results could help shape future therapies for humans, especially as GLP-1 agonists like semaglutide and liraglutide have already made headlines for their dual roles in diabetes and weight management. Jeb Besser, CEO of Modular Medical stated, “We are excited to share our findings from this novel study in the DIO mouse comparing the pump delivery of exenatide to intermittent dosing of semaglutide. Given the high rate of gastrointestinal tolerability challenges and resultant discontinuation that is characteristic of GLP-1 therapy, we believe that a personalized approach to GLP-1 titration and dosing, including a mealtime bolus option, would give patients an opportunity to reach their treatment goals, while experiencing easier therapy initiation and a more tolerable maintenance regimen.”

Why Pumps? Why Now?

Insulin pumps have long been the domain of the highly motivated “super user,” but Modular Medical is on a mission to democratize this technology. Their two-part patch pump is engineered to be as approachable as a cup of coffee—no PhD required. The company’s upcoming MODD2 system aims to integrate continuous glucose monitoring and algorithm-driven dosing, nudging the market closer to a closed-loop “artificial pancreas” that could make day-to-day diabetes management nearly hands-off.

This modular approach isn’t just a clever branding exercise. In biomedical research and clinical data management, modularity is the secret sauce that enables flexibility, scalability, and rapid innovation. Platforms like Medical-Blocks and IMPatienT, for example, use modular architectures to streamline data collection, analysis, and sharing across research teams and institutions, making it easier to adapt to new challenges and opportunities. In the context of Modular Medical’s work, this is believed to mean faster adaptation to new therapies and patient needs.

Financial Footing and Analyst Sentiment

Of course, no tale of medical innovation is complete without a peek at the balance sheet. Modular Medical remains a pre-revenue company, investing heavily in research and development—$14.7 million in the last fiscal year alone, a 14% jump as they ramp up for commercialization. Despite reporting a net loss of $18.8 million for the year, Wall Street’s consensus remains bullish, with analysts maintaining “buy” ratings and a median 12-month price target of $8.00 per share and is curtly trading in the $.80 range. Insiders, too, have shown confidence, recently snapping up over half a million dollars in company stock. Modular Medical announced on March 20, 2025 the execution of definitive subscription agreements with institutional and accredited investors for a private placement, which was expected to result in gross proceeds of approximately $12 million, before deducting fees and offering expenses.

The Broader Context: Modularity in Modern Medicine

The modular ethos extends well beyond pumps and mice. In epidemiological studies and patient data management, modular systems like MOSAIC and Medical-Blocks are helping researchers tackle the complexities of multi-site data collection, privacy, and consent with pre-programmed modules and standardized templates. This trend toward modularity is accelerating the pace of discovery and making it easier to translate benchside breakthroughs into bedside realities.

Looking Ahead

As Modular Medical prepares to share its latest findings with the ADA community, the company stands at the intersection of innovation, accessibility, and real-world impact. By combining modular technology with a focus on user experience, they’re not only making advanced diabetes care more approachable—they’re setting the stage for a new era of patient-centered, data-driven medicine.

So, while the mice may have done the heavy lifting in this study, the implications could be far-reaching. With a wink to modularity and a nod to the future, Modular Medical’s journey is one to watch—whether you’re a clinician, a patient, or just a fan of clever solutions to complex problems.